Sonnet BioTherapeutics Holdings, Inc. (SONN)

Dec 2, 2025 - SONN was delisted (reason: merged into PURR)

1.260

-1.840 (-59.35%)

Inactive · Last trade price on Dec 2, 2025

-50.97% (1Y)

Market Cap	8.60M
Revenue (ttm)	1,000,000
Net Income (ttm)	-13.56M
Shares Out	6.83M
EPS (ttm)	-5.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,456,154
Open	3.160
Previous Close	3.100
Day's Range	1.260 - 3.230
52-Week Range	1.030 - 19.300
Beta	1.47
Analysts	Strong Buy
Price Target	20.00 (+1,487.3%)
Earnings Date	Dec 12, 2025

About SONN

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck c... [Read more]

Industry Biotechnology

Sector Healthcare

CEO Raghu Rao

Employees 13

Stock Exchange NASDAQ

Ticker Symbol SONN

Website https://www.sonnetbio.com

Full Company Profile

Financial Performance

In 2024, SONN's revenue was $18,626, a decrease of -87.40% compared to the previous year's $147,805. Losses were -$7.44 million, -60.51% less than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for SONN stock is "Strong Buy" and the 12-month stock price target is $20.0.

Price Target

$20.0

(1,487.30% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

There is no news available yet.